Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Cash (2021 - 2025)

Historic Change in Cash for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $38.8 million.

  • Krystal Biotech's Change in Cash rose 3759.76% to $38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 247075.86%. This contributed to the annual value of -$13.5 million for FY2024, which is 10685.39% down from last year.
  • Per Krystal Biotech's latest filing, its Change in Cash stood at $38.8 million for Q3 2025, which was up 3759.76% from $45.1 million recorded in Q2 2025.
  • Krystal Biotech's Change in Cash's 5-year high stood at $135.1 million during Q2 2023, with a 5-year trough of -$72.6 million in Q2 2021.
  • For the 5-year period, Krystal Biotech's Change in Cash averaged around $6.5 million, with its median value being -$14.9 million (2023).
  • Examining YoY changes over the last 5 years, Krystal Biotech's Change in Cash showed a top increase of 44083.96% in 2025 and a maximum decrease of 542374.63% in 2025.
  • Krystal Biotech's Change in Cash (Quarter) stood at $54.6 million in 2021, then tumbled by 144.86% to -$24.5 million in 2022, then skyrocketed by 39.15% to -$14.9 million in 2023, then crashed by 95.14% to -$29.1 million in 2024, then skyrocketed by 233.24% to $38.8 million in 2025.
  • Its last three reported values are $38.8 million in Q3 2025, $45.1 million for Q2 2025, and -$36.1 million during Q1 2025.